A new study confirms a link between the severity of symptoms for those with chronic pain and atmospheric weather conditions. Low atmospheric pressure was associated with more severe symptoms of pain.
A newly developed peptide called Tat-P4-(C5)2 is targets and only affects nerve changes that pose a problem resulting in chronic pain. Previous studies have also shown the peptide can also reduce addiction.
Study reveals how a neuropeptide called Big Dynorphin binds to the acid-sensing ion channel receptor, causing pain signals to be sent around the body.
Meta-analysis of previous studies reveals cannabinoid treatments produce a small, but significant reduction in subjective pain scores for sufferers of chronic pain.
M2 macrophages can produce various endogenous opioids, such as endorphins, enkephalin, and dynorphin, which activate opioid receptors at the site of inflammation.
Intercepting CCL2 with specific antibodies may provide an early intervention for chronic neuropathic pain.
Researchers discover the amygdala is a critical site of action for pain modulation. An existing compound, LY379268, provides pain-relieving effects and helps to reduce anxiety.
Inhibitory inputs to the neural circuit between the dorsolateral bed nucleus of the stria terminalis (dlBNST) to the ventral tegmental area (VTA) increase when a person is in chronic pain. This alteration is mediated by enhanced corticotropin-releasing factor signaling within the dlBNST, leading to suppression of the mesolimbic dopaminergic system. The result is depressive mood and anhedonia associated with chronic pain.
WaTx, a short protein in the venom of Australian Black Rock scorpions, is helping researchers uncover new information about chronic pain and inflammation.
Blocking the activity of interleukin-1 in mouse models of complex regional pain syndrome (CRPS) helped reverse symptoms. Researchers say patients with CRPS should respond to immune-based treatments which reduce some of the disease features.
Opioids are often prescribed to help those with chronic pain manage sleep problems associated with their condition. New research reports opioids effect on sleep quality is limited and of poor quality. Additionally, opioids can increase the risk of sleep apnea.
A new biomarker for fibromyalgia has been identified in blood samples taken from patients suffering from the condition.
